# Parexel

Source: https://onco.cc/companies/parexel/  
OnCo record `parexel` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Parexel, of Durham, North Carolina, is a global contract research organisation owned by EQT and Goldman Sachs that runs early and late-phase oncology trials and sells regulatory consulting staffed by former FDA officials. Whether regulators moving into consulting sharpens trial design or blurs the line between regulator and industry is the question its model raises.

## Summary

Parexel, based in Durham, North Carolina, is a global contract research organisation known for regulatory consulting staffed by former FDA officials and for its oncology trial operations. It is privately owned by EQT and Goldman Sachs and works across regulatory strategy, early-phase and late-phase oncology development. OnCo links it to contract research organisations. Whether the movement of regulators into consulting sharpens trial design or blurs the line between regulator and industry is the fair question its model raises. The CRO technology page carries the wider picture.

## Fields

- Kind: Company
- Last checked: 2026-09-08
- Tags: supporting
- HQ: Durham, NC
- Type: cro-services
- Website: https://www.parexel.com

## Sources

- Official website: https://www.parexel.com

## Connected records

- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/)
- technologies: [Contract research organisations (CROs)](https://onco.cc/technologies/contract-research-organisations/)
- trials: [A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma](https://onco.cc/trials/nct07069712/), [A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors](https://onco.cc/trials/nct04452955/), [BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants](https://onco.cc/trials/nct05943106/), [Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)](https://onco.cc/trials/nct05629234/)

---
JSON: https://onco.cc/api/v1/entities/parexel.json